Recros Medica, Inc. today announced the closing of a $14 million Series A preferred stock financing.

Recros Medica, Inc. announced today that its de novo regulatory submission for the Nuvellus™ Focal Contouring System has been accepted for review by the US Food and Drug Administration (FDA). Nuvellus™, which utilizes the company’s proprietary Rotational Fractional Resection (RFR) technology, may provide medical aesthetic physicians a minimally-invasive single treatment option to improve submental (neck and jowl) contouring.

SAN DIEGO, Oct. 9, 2018 /PRNewswire/ — Recros Medica, Inc. announced today it will showcase its Rotational Fractional Resection (RFR) platform at the 2018 American

SAN DIEGO, CA, September 27, 2018 – Recros Medica, Inc., an aesthetic medical device company focused on developing devices to reduce skin laxity and improve

SAN DIEGO, June 19, 2018 /PRNewswire/ — Recros Medica, Inc., an aesthetic medical device company focused on developing devices to reduce skin laxity and improve focal contouring through

SAN DIEGO, CA, January 4, 2018 – Recros Medica, Inc., a development stage medical aesthetic device company focused on reducing skin laxity and focal contouring,

SAN DIEGO, CA, September 18, 2017 – Recros Medica, Inc., a development stage medical aesthetic device company focused on reducing skin laxity and focal contouring,